 In September 2006, an Institute of Medicine report commissioned by the FDA found that its drug safety system is limited by inadequate funding, insufficient regulatory authority, and a lack of oversight by experts free of pharmaceutical industry ties.The FDA launched a new program in 2005 to provide drug risk information directly to the public through internet-accessible drug sheets and bulletins.The enactment of the Food and Drug Administration Amendments Act of 2007 (FDAAA), expanded the authority of the FDA over drug safety monitoring after approval and introduction for use by the public.